Insilico Medicine Included in Hong Kong Stock Exchange Tech 100 Index, AI Industry Opportunities Gain Attention

Insilico Medicine, a clinical-stage drug development technology company driven by generative artificial intelligence (AI), has announced its inclusion in the Hong Kong Stock Exchange Tech 100 Index. The index changes will take effect after the market closes on September 11, 2026, with the new components becoming effective from September 14, 2026. The Hong Kong Stock Exchange recently optimized the index compilation plan on August 18, aiming to broaden the index’s coverage of emerging technology trends, including opportunities in the AI industry chain. The HKEX Tech 100 Index, where Insilico Medicine will be included, consists of industry leaders and emerging enterprises…